- Home
- People
- CLINUVEL news
A Podcast by CLINUVEL: Behind the label — what is takes to launch safe and effective cosmetics
CLINUVEL’s Regulatory Affairs Manager (Cosmetics), Alice Lynn, is back in this episode to demystify the labels on cosmetic products and explore how brands determine shelf life and efficacy claims. Tune in to learn what it takes to get a safe, effective, and innovative cosmetic from the lab to your vanity table.CLINUVEL newsA Podcast by CLINUVEL: “How did they get it so wrong?” — Unpacking SPF testing
In this podcast episode, CLINUVEL’s Regulatory Affairs Project Manager (Cosmetics), Alice Lynn joined Sarah Mawson to unpack SPF: what is it? How do we test for it? And why some labels may not be what they seem.CLINUVEL newsA Podcast by CLINUVEL: Insights from Dr Emilie Rodenburger on CLINUVEL’s vitiligo program
In this podcast episode, Dr Emilie Rodenburger, Director, Global Clinical Affairs at CLINUVEL, elaborates on the scientific basis for using afamelanotide in vitiligo, and provides insights on key learnings from the program to date.CLINUVEL newsAddressing the unmet needs of vitiligo patients: Non-Executive Director Dr Pearl Grimes
Dr Grimes, Non-Executive Director at CLINUVEL, discusses the current treatment landscape in the field of vitiligo—including the positive progress in regulatory issues and reimbursement of treatment—as well as the future for vitiligo patients.
- R&D
- CLINUVEL news
A Podcast by CLINUVEL: Behind the label — what is takes to launch safe and effective cosmetics
CLINUVEL’s Regulatory Affairs Manager (Cosmetics), Alice Lynn, is back in this episode to demystify the labels on cosmetic products and explore how brands determine shelf life and efficacy claims. Tune in to learn what it takes to get a safe, effective, and innovative cosmetic from the lab to your vanity table.CLINUVEL newsA Podcast by CLINUVEL: “How did they get it so wrong?” — Unpacking SPF testing
In this podcast episode, CLINUVEL’s Regulatory Affairs Project Manager (Cosmetics), Alice Lynn joined Sarah Mawson to unpack SPF: what is it? How do we test for it? And why some labels may not be what they seem.CLINUVEL newsA Podcast by CLINUVEL: Insights from Dr Emilie Rodenburger on CLINUVEL’s vitiligo program
In this podcast episode, Dr Emilie Rodenburger, Director, Global Clinical Affairs at CLINUVEL, elaborates on the scientific basis for using afamelanotide in vitiligo, and provides insights on key learnings from the program to date.CLINUVEL newsAddressing the unmet needs of vitiligo patients: Non-Executive Director Dr Pearl Grimes
Dr Grimes, Non-Executive Director at CLINUVEL, discusses the current treatment landscape in the field of vitiligo—including the positive progress in regulatory issues and reimbursement of treatment—as well as the future for vitiligo patients.
- Publications
- Publications
The Weekend Effect – A Worrying Truth or Myth?
Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...PublicationsIs skin cancer in your job description?
Those of us working from offices, or our own homes, aren’t expecting danger pay. However, what about those who have jobs that heighten the risk of getting skin...PublicationsTomatoes and carrots… photoprotection from within?
Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...PublicationsHas COVID-19 Had an Effect on Sun Protection Behaviours?
Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...
- Finance & investing
- CLINUVEL news
CLINUVEL FY2025 Annual Results – Investor Webinar
CLINUVEL hosted an investor webinar following the release of its FY2025 results on 28 August 2025. Mr Malcolm Bull, Head of Investor Relations and Australia Operations, is joined by Mr Peter Vaughan, Chief Financial Officer, and Dr Philippe Wolgen, Managing Director, to review the results.CLINUVEL newsFirst half results – FY2025
CLINUVEL (ASX:CUV) hosted an investor webinar to review the half year results and operational highlights for the six months ended on 31 December 2024.CLINUVEL newsA focused strategy that must continue: Non-Executive Director Guy van Dievoet
Guy van Dievoet was appointed Non-Executive Director in 2024, alongside Matthew Pringle and Dr Pearl Grimes. In a video in February 2025, he elaborates on the Company’s approach to creating value as a speciality pharmaceutical group and pursuing M&A opportunities.CLINUVEL newsCLINUVEL is on the cusp of realising exciting opportunities: Non-Executive Director Matthew Pringle
Matthew Pringle joined CLINUVEL as a Non-Executive Director in 2024. In this video released in February 2025, Mr Pringle discusses the role of Directors, and the Company’s approach to capital management and building long-term incremental value as it works to realise its objectives.